Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.02 by 4800 percent. This is a 380 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $70.00 million which beat the analyst consensus estimate of $17.50 million by 300.00 percent.